G
Gülin Öz
Researcher at University of Minnesota
Publications - 125
Citations - 5582
Gülin Öz is an academic researcher from University of Minnesota. The author has contributed to research in topics: Spinocerebellar ataxia & Neurochemical. The author has an hindex of 38, co-authored 110 publications receiving 4355 citations.
Papers
More filters
Journal ArticleDOI
N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases.
Mary Holmay,Melissa Terpstra,Lisa D. Coles,Usha Mishra,Matthew Ahlskog,Gülin Öz,James C. Cloyd,Paul J. Tuite +7 more
TL;DR: This work shows the potential utility of MRS monitoring, which could assist in determining dosing regimens for clinical trials of this potentially useful antioxidant therapy for PD disease, GD, and other neurodegenerative disorders.
Journal ArticleDOI
Elevated Pontine and Putamenal GABA Levels in Mild-Moderate Parkinson Disease Detected by 7 Tesla Proton MRS
TL;DR: In vivo evidence is provided for an alteration in the GABAergic tone in the lower brainstem and striatum in early-moderate PD, which may underlie disease pathogenesis and may provide a biomarker for disease staging.
Journal ArticleDOI
Preprocessing, analysis and quantification in single‐voxel magnetic resonance spectroscopy: experts' consensus recommendations
Jamie Near,Jamie Near,Ashley D. Harris,Ashley D. Harris,Ashley D. Harris,Christoph Juchem,Roland Kreis,Małgorzata Marjańska,Gülin Öz,Johannes Slotboom,Martin Wilson,Charles Gasparovic +11 more
TL;DR: These three main steps in the post‐acquisition workflow of a single‐voxel MRS experiment (preprocessing, analysis and quantification) are reviewed and recommendations for best practices at each step are provided.
Journal ArticleDOI
Localized in vivo 13C NMR spectroscopy of the brain.
TL;DR: It is concluded that the unique and novel insights provided by 13C NMR spectroscopy have opened many new research areas that are likely to improve the understanding of brain carbohydrate metabolism in health and disease.
Journal ArticleDOI
Spinocerebellar ataxias: prospects and challenges for therapy development
TL;DR: MRI and magnetic resonance spectroscopy have emerged as potentially powerful biomarkers for disease activities and progression, but target engagement biomarkers, especially molecular biomarkers in biofluids, are yet to be developed.